These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Personalized Care and the Role of Insulin as a Vehicle to Optimizing Treatments in Diabetes Care. Bieszk N, Grabner M, Wei W, Barron J, Quimbo R, Yan T, Biel B, Chu JW. J Manag Care Spec Pharm; 2017 Nov; 23(11):1160-1168. PubMed ID: 29083969 [Abstract] [Full Text] [Related]
9. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. Menzin J, Korn JR, Cohen J, Lobo F, Zhang B, Friedman M, Neumann PJ. J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217 [Abstract] [Full Text] [Related]
10. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population. Bergeson JG, Worley K, Louder A, Ward M, Graham J. J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475 [Abstract] [Full Text] [Related]
11. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease. Mehta S, Ghosh S, Sander S, Kuti E, Mountford WK. J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954 [Abstract] [Full Text] [Related]
12. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population. Grabner M, Peng X, Geremakis C, Bae J. J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969 [Abstract] [Full Text] [Related]
13. Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United States. Joish VN, Zhou FL, Preblick R, Lin D, Deshpande M, Verma S, Davies MJ, Paranjape S, Pettus J. J Manag Care Spec Pharm; 2020 Mar; 26(3):311-318. PubMed ID: 32105172 [Abstract] [Full Text] [Related]
14. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control. Karkare S, Fridman M, Dang-Tan T, Lu J, Smolarz BG, DeKoven M, Iyer NN. J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232 [Abstract] [Full Text] [Related]
18. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis. Xie L, Zhou S, Pinsky BW, Buysman EK, Baser O. Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083 [Abstract] [Full Text] [Related]
19. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population. Buono JL, Mathur K, Averitt AJ, Andrae DA. J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443 [Abstract] [Full Text] [Related]